GlassScriptPhysician profile
Mollie Steiner
NPI 1750161071
$2,984.20
in general payments reported to CMS, 2019-2025
31 companies · $972 in 2025
The $972 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $668 · 2024: $1,344 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $429.49 | 2023-2025 | Prolaris |
| Dendreon Pharmaceuticals LLC | $347.56 | 2023-2025 | Provenge |
| Boston Scientific Corporation | $266.04 | 2024-2025 | Axonics, General - Erectile Dysfunction |
| Sumitomo Pharma America, INC. | $255.80 | 2024-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $248.04 | 2023-2025 | |
| Pfizer INC. | $162.86 | 2024-2025 | |
| Janssen Biotech, INC. | $156.52 | 2023-2025 | Erleada, Akeega |
| Endo USA, INC. | $135.07 | 2024-2025 | Aveed, Xiaflex |
| Axonics, INC. | $114.74 | 2024 | Axonics |
| Ferring Pharmaceuticals INC. | $99.28 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $76.17 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $75.94 | 2024-2025 | |
| Blue Earth Diagnostics | $63.33 | 2024-2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $60.86 | 2024 | |
| Progenics Pharmaceuticals, INC. | $59.49 | 2023-2025 | Pylarify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $48.70 | 2024-2025 | Echelon Flex, Surgicel Nu-Knit, Enseal |
| Accord Healthcare, INC. | $42.74 | 2024 | |
| Astellas Pharma US INC | $40.42 | 2024-2025 | Veozah, Xtandi |
| Civco Medical Instruments | $37.51 | 2023 | |
| Teleflex LLC | $35.69 | 2023-2024 | Urolift |
| Tolmar, INC. | $31.16 | 2025 | Jatenzo, Eligard |
| Endo Pharmaceuticals INC. | $28.93 | 2023 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $26.90 | 2024 | Welireg, Keytruda |
| Urogen Pharma, INC. | $25.37 | 2025 | |
| Smith+Nephew, INC. | $20.52 | 2024 | Stravix |
| Astrazeneca Pharmaceuticals LP | $20.11 | 2023 | Lynparza |
| Immunitybio, INC. | $16.99 | 2025 | |
| Antares Pharma, INC. | $16.06 | 2024 | Xyosted |
| Coloplast Corp | $14.29 | 2025 | |
| Ambu INC. | $14.16 | 2024 | |
| Angiodynamics, INC. | $13.46 | 2024 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mollie Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.